Vanguard Portfolio Management
RVMD icon

Vanguard Portfolio Management’s Revolution Medicines RVMD Stock Holding History

Vanguard Portfolio Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.55B Buy
8,294,855
+792,232
+11% +$116M 0.07% 307
2026
Q1 		$730M Buy
+7,502,623
New +$758M 0.04% 506

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management's RVMD Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Revolution Medicines (RVMD) stake by 11% in Q2 2026, buying an estimated $116M and bringing the position to 8,294,855 shares worth $1.55B. The position accounts for 0.07% of the portfolio, ranked #307.

Vanguard Portfolio Management first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 637 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • Vanguard Portfolio Management held 8,294,855 shares of Revolution Medicines worth $1.55B as of Q2 2026.
  • Vanguard Portfolio Management bought 792,232 Revolution Medicines shares in Q2 2026, an estimated $116M.
  • Revolution Medicines made up 0.07% of Vanguard Portfolio Management's portfolio in Q2 2026, its #307 holding.
  • Vanguard Portfolio Management first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
  • 637 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.